Carbohydrate Metabolism and Lactate
1 Glucose Utilization
Abnormal glucose handling occurs in ME/CFS:
- Hypoglycemia symptoms: Reported by many patients, though blood glucose often normal
- Impaired glucose uptake: May affect specific tissues
- Altered insulin sensitivity: Variable findings
- Post-prandial symptoms: Reactive responses to meals
2 Lactate Accumulation
Elevated lactate indicates reliance on anaerobic metabolism:
- Resting lactate: May be elevated in some patients
- Exercise lactate: Earlier and greater accumulation
- Recovery: Slower lactate clearance
Lactate is not only a metabolic waste product: it is also a signaling molecule (GPR81/HCAR1) whose receptor and transporter axis is discussed in Virtual Hypoxia: An Internal-Study Neuro-Metabolic Picture. Whether lactate is an active participant or an inert marker in ME/CFS is an open question developed there.
- Brain lactate: Elevated on MR spectroscopy in some studies
Clinical Phenomenology: Similarities to Athletic Post-Exercise States.
The chronic lactate accumulation and reliance on anaerobic metabolism in ME/CFS produces a muscle metabolic state remarkably similar to what elite athletes experience temporarily after exhausting physical efforts:
- Muscle cramping: ATP depletion prevents proper muscle relaxation; magnesium and calcium handling disrupted
- “Ready for cramps” sensation: Persistent partial ATP deficit maintains muscles in pre-cramp tension state
- Metabolic acidosis: Lactate accumulation creates acidic intracellular environment
- Delayed recovery: Impaired lactate clearance prolongs metabolic stress
The critical difference: athletes experience this state transiently after intense exertion and recover within hours to days; ME/CFS patients exist in this state continuously, even at rest or after minimal activity.
This parallel has practical treatment implications. Sports medicine recovery protocols—electrolyte replacement, magnesium supplementation, ATP precursors (D-ribose), lactate clearance strategies—may provide symptomatic benefit by addressing the chronic metabolic stress state. These recovery strategies informed the development of baseline metabolic support protocols discussed in the treatment chapters.
ME/CFS muscle pathophysiology may be understood as a state of continuous post-exercise metabolic stress without the triggering exercise. Interventions that support athletic recovery from intense exertion may provide baseline metabolic support for ME/CFS patients:
- Oral rehydration solutions for blood volume and lactate clearance
- Magnesium for ATP synthesis and muscle relaxation
- Acetyl-L-carnitine to restore fat oxidation capacity
- D-ribose as direct ATP building block
This framework suggests ME/CFS patients require continuous application of recovery protocols, not as performance enhancement but as compensatory support for chronically impaired energy metabolism.
Certainty: 0.40. (Raw certainty 0.40 — Vienna preprint, not yet peer-reviewed, n=26 patients / 27 controls; ME/CFS population weight 1.0 → discounted 0.40.) A proof-of-concept multimodal MRI study exposed ME/CFS patients and controls to normoxia plus two controlled hypoxic challenges (SpO2 ~87%) while measuring cerebral metabolites and blood flow (Bader et al. 2026). Patients showed an elevated resting thalamic lactate-to-creatine ratio (Lac/tCr) at baseline: 0.171 vs 0.135 in controls (~27% higher; \(\beta\)=0.035, \(p\)=0.021); white-matter Lac/tCr did not differ. Under hypoxia, control thalamic Lac/tCr rose (H1 \(p\)=0.028, H2 \(p\)=0.039), but patients’ did not (H1 \(p\)=0.38, H2 \(p\)=0.46) — already elevated at baseline. Because the “blunted” patient response is a null (a failure to detect a rise in a modest sample), it should not be read as strongly as a demonstrated group difference; a ceiling or regression-to-the-mean effect (patients already elevated, leaving less room to rise) is a plausible alternative to genuine blunted reactivity. This is consistent with the “virtual hypoxia” hypothesis: the brain behaves as if under chronic oxygen limitation despite normal arterial oxygenation, reflecting intrinsic mitochondrial/bioenergetic inefficiency with a glycolytic shift (Trapp and Stys 2009) (Tomas et al. 2017). The authors note that elevated baseline brain lactate is “consistent with the most reproducible spectroscopic finding in ME/CFS — increased ventricular and cerebral lactate” (Bader et al. 2026).
Replication status: Not yet replicated. This is a single preprint; the finding is consistent with prior spectroscopy evidence of elevated brain lactate but the specific blunted-reactivity pattern is novel.
Severity applicability: Unknown — the study cohort was not stratified by severity; whether the resting-lactate elevation and blunted metabolic reactivity differ across disease severity levels is not established.
Limitations: Proof-of-concept design with a modest sample; cross-sectional; the hypoxic challenge is a controlled physiological stressor and cannot be directly attributed to post-exertional malaise, because it is not physical exertion. The blunted-reactivity claim rests on a null patient response that could reflect a ceiling/regression-to-mean effect rather than genuine impaired reactivity. Exploratory analyses (network coupling) are hypothesis-generating.
Falsifiable prediction: If virtual hypoxia reflects intrinsic bioenergetic inefficiency, then resting brain lactate should remain elevated (or show a blunted rise) in patients across a second independent cohort, and an intervention that restores mitochondrial ATP production (e.g., metabolic support targeting the PDH/glycolytic balance) should normalise the resting lactate signal.
Consequence: This finding supports the view that ME/CFS fatigue is accompanied by a measurable brain metabolic signature — an inability to ramp up energy production on demand — rather than purely psychological or motivational causes, and gives researchers a concrete imaging readout to track.
The experimental-hypoxia probe and its cross-disease framing suggest that ME/CFS may involve a brain behaving as if under chronic energy limitation despite normal arterial oxygenation — a “virtual hypoxia” state of impaired neuro-metabolic adaptive capacity (Bader et al. 2026). These environments are internally consistent — elevated resting brain lactate that fails to ramp up under a controlled hypoxic stressor (Virtual Hypoxia: Elevated Resting Brain Lactate with Blunted Metabolic Reactivity) and preserved gross cerebrovascular reactivity but greater initial response variability (Preserved Gross Cerebrovascular Reactivity but Greater Inter-Individual Variability) both derive from the same single preprint, and the pattern extends the bioenergetic-inefficiency logic developed in multiple sclerosis as a mechanistic bridge rather than an identity (Multiple Sclerosis “Virtual Hypoxia” as a Mechanistic Template — Not an Identity). They should not be read as independent replications: this is one proof-of-concept study plus a conceptual bridge, not three converging bodies of evidence. Two constraints remain open: the direction of any brainstem volume difference is unresolved across cohorts (Brainstem Volume Direction Contradicts Across Cohorts), and whether elevated brain lactate can stratify patients for tissue-oxygenation or mitochondrial-targeted trials is hypothesis-generating, not validated (Thalamic Lac/tCr as a Candidate Stratification Biomarker for Energy-Metabolism Trials). What the evidence supports is a measurable, mechanism-proximal brain metabolic signature of the disease; what remains speculative is its causal role, its severity stratification, and any therapeutic implication. The most important open question is whether this resting metabolic signature is a cause of ME/CFS fatigue or a downstream epiphenomenon of a more proximal defect.
Consequence: These findings give researchers and clinicians a concrete, mechanism-anchored brain readout — elevated resting lactate and a blunted metabolic response to challenge — that could eventually help define a biologically distinct “brain-energy-deficient” subgroup, but only after independent replication and prospective validation; they do not yet support any treatment recommendation.
3 Lactate as a Signaling Molecule
Lactate is conventionally described as a metabolic waste product, and in ME/CFS it is usually presented only as a marker of glycolytic strain (Carbohydrate Metabolism and Lactate, Virtual Hypoxia: Elevated Resting Brain Lactate with Blunted Metabolic Reactivity). In animal and in-vitro model systems, lactate is also an active signal: it is the endogenous ligand of the G-protein-coupled receptor GPR81 (also called HCAR1), and it carries signaling functions in adipose tissue, the immune system, and the brain (Ahmed et al. 2010) (Hoque et al. 2014) (Colegio et al. 2014) (Pucino et al. 2019) (Yang et al. 2014) (Morland et al. 2017). Its distribution between cells and compartments is controlled by the monocarboxylate transporters MCT1–4 (SLC16A) (Halestrap and Wilson 2012). This reframes the elevated lactate documented in a subset of ME/CFS patients: lactate is not only a marker of glycolytic strain, it is a candidate signal whose receptor and transporter axis has never been measured in ME/CFS patients.
Certainty: 0.35. (Raw certainty 0.70, from animal/in-vitro model systems → discounted to 0.35 by the population-relevance weight 0.50.) Lactate is the native ligand for GPR81/HCAR1, a Gi-coupled receptor that signals in adipocytes (suppressing lipolysis) (Ahmed et al. 2010), in innate immune cells (dampening TLR/NLRP3-driven inflammation) (Hoque et al. 2014), in macrophages (polarizing metabolism) (Colegio et al. 2014), in CD4+ T cells (rewiring inflammatory effector function) (Pucino et al. 2019), and in the brain (modulating plasticity) (Yang et al. 2014) and cerebrovascular signaling (Morland et al. 2017). If the chronically elevated lactate documented in a subset of ME/CFS patients were to engage these receptors, it would make lactate an active participant in the neuro-immune-metabolic phenotype rather than a passive readout.
Evidence type: Animal and in-vitro model systems only. Translation gap: GPR81/HCAR1 expression and lactate-stimulated signaling have not been measured in ME/CFS patients (model system → human, not yet validated in ME/CFS).
Replication status: The receptor mechanism is replicated across independent laboratories for adipose, immune, and brain tissue; it has not been tested in ME/CFS.
Severity applicability: Unknown — no ME/CFS study stratifies GPR81/HCAR1 signaling by disease severity.
Competing explanation: Elevated lactate may be an inert by-product with no downstream signaling role in ME/CFS. The elevation is also not uniform: in a 7T magnetic resonance spectroscopy comparison, ME/CFS patients showed elevated brain (anterior-cingulate) lactate while resting calf-muscle metabolites did not differ from controls (Godlewska et al. 2025) — consistent with a compartment-specific rather than systemic elevation, or with lactate being incidental to the upstream energy failure.
Limitations: The entire receptor arm rests on model-system evidence; a receptor that signals in isolated adipocytes or cell lines need not be engaged at pathophysiological ligand concentrations in patients. Concentration-dependence, receptor desensitization, and tissue accessibility are unmeasured in ME/CFS.
Falsifiable prediction: GPR81/HCAR1 expression or lactate-stimulated signaling (e.g., cAMP suppression, downstream effector phosphorylation) will differ between ME/CFS patients and controls in an accessible tissue (PBMC or muscle), and will correlate with post-exertional symptom severity; falsified if no ME/CFS-control difference is detected, or if any difference is explained entirely by circulating lactate concentration without receptor-axis change.
Consequence: If confirmed, this would turn lactate from a symptom marker into a treatment target and would explain why elevated lactate could produce immune and neurological effects rather than merely reflecting them — but the hypothesis is currently unmeasured in patients and could be wrong.
Certainty: 0.30. Lactate movement between muscle, blood, and brain is gated by the proton-linked monocarboxylate transporters MCT1–MCT4 (SLC16A family), which set the direction and rate of lactate flux (Halestrap and Wilson 2012). The astrocyte–neuron lactate shuttle — already modeled in this chapter (Compartmental Energy Models) — depends on this transport step (Magistretti and Allaman 2018). If MCT expression or proton-coupled transport capacity were reduced in ME/CFS, impaired lactate clearance (described as slower recovery, though not yet measured as a kinetic endpoint) could coexist with preserved or increased lactate production, raising local and systemic lactate even without a change in glycolytic rate.
Evidence type: General cell-biology and transport-kinetics evidence; no ME/CFS measurement. Translation gap: MCT1–4 expression and transport kinetics are unmeasured in ME/CFS tissue.
Replication status: MCT family biology is well-replicated; the ME/CFS-specific claim is untested.
Severity applicability: Unknown — no severity-stratified data.
Competing explanation: Slower lactate clearance could reflect reduced tissue perfusion or mitochondrial oxidation rather than a transporter defect; the same functional observation is consistent with several upstream causes.
Limitations: No MCT expression, membrane localization, or transport-flux data exist in ME/CFS; assigning a rate-limiting role to transport requires direct flux measurement, not inference from clearance curves.
Falsifiable prediction: In ME/CFS muscle or PBMC, MCT1/MCT4 expression or lactate transport flux will be reduced relative to controls at matched circulating lactate, and will correlate with delayed post-exertional lactate clearance; falsified if transport capacity is normal or if clearance delay is fully accounted for by perfusion or oxidation rate.
Consequence: A transport bottleneck would suggest a different target from a production bottleneck — improving clearance rather than suppressing glycolysis — and would make MCT expression a measurable, testable node in ME/CFS.
Does lactate, acting as a signal rather than a waste product, contribute to ME/CFS symptoms — and if so, through which tissue? Three non-exclusive candidate routes exist: immune (GPR81-mediated suppression of innate inflammation (Hoque et al. 2014), macrophage polarization (Colegio et al. 2014), CD4+ T-cell rewiring (Pucino et al. 2019)), adipose/metabolic (antilipolysis (Ahmed et al. 2010)), and central (NMDA-mediated plasticity (Yang et al. 2014), cerebrovascular signaling (Morland et al. 2017)). Each route makes a different prediction about which symptoms would track lactate and which tissue would show receptor-axis change. The question is currently unresolvable because neither GPR81/HCAR1 expression nor lactate-stimulated signaling has been measured in ME/CFS patients. (Severity applicability: unknown — no severity-stratified data.)
Consequence: Answering this would determine whether lactate is a passive marker or an active driver in ME/CFS, and would decide whether the receptor axis is a plausible treatment target or a dead end.
The signaling interpretation of lactate in ME/CFS rests entirely on model-system evidence; no study has measured GPR81/HCAR1 expression, MCT1–4 expression, or lactate-stimulated signaling in ME/CFS patients. Lactate elevation is also not uniform — the 7T MRS finding is a compartment-specific brain (anterior-cingulate) elevation, while resting calf-muscle metabolites in the same study did not differ from controls (Godlewska et al. 2025) — so the assumed ligand may be present in only a subset of patients, and its tissue distribution is unmeasured. Until the receptor and transporter axis is measured in patients, lactate signaling in ME/CFS remains a mechanistically plausible but untested hypothesis. This is the single largest evidence gap for this topic.
Consequence: Without direct measurement, no clinical claim about lactate signaling in ME/CFS can be made; the practical implication is that lactate currently guides no ME/CFS-specific diagnostic or treatment decision beyond the general energy-metabolism context.
(Origin: brainstorm.) The best-replicated lactate finding in ME/CFS is a compartment-specific brain elevation on magnetic resonance spectroscopy (Godlewska et al. 2025), not a uniform systemic rise; whether post-exertional clearance is slowed is described clinically but has not been measured as a kinetic endpoint. The untested candidate is the shape of the post-exertional lactate curve: peak height and clearance rate, measured by submaximal two-day cardiopulmonary exercise testing or by an at-home finger-prick series (handheld lactate meters exist, though capillary-meter accuracy is limited and frequent sampling may itself be burdensome in severe disease). If clearance kinetics separate ME/CFS patients from activity-matched controls and improve with a lactate-lowering intervention, lactate becomes an objective monitoring number for a crash or a treatment response, alongside patient report. (Severity applicability: unknown — no study has measured clearance kinetics by severity.)
Consequence: It would give patients and clinicians an objective number to watch, turning “how do I clear lactic acid?” from a subjective question into a measurable quantity — if the kinetics prove discriminating.
(Origin: brainstorm.) Every signaling claim in this subsection rests on animal or in-vitro evidence, because no study has measured GPR81/HCAR1 expression, MCT1–4 expression, or lactate-stimulated signaling in ME/CFS patients. A single severity-stratified cohort measuring the receptor/transporter axis in an accessible tissue (PBMC, and muscle where feasible) — ideally with post-exertional venous-lactate kinetics as a co-primary endpoint — would convert the strongest open question here into data, and could stratify patients into those in whom lactate signaling matters and those in whom it does not. Until that measurement exists, the mechanism remains untested. (Severity applicability: unknown by design — this study is what would establish it.)
Consequence: This is the one measurement that would decide whether the entire lactate-signaling arm is real in patients or remains a model-system artifact.
The evidence above converges on a single reframing: lactate is not merely a metabolic waste product but a signaling molecule (GPR81/HCAR1) whose receptor and transporter axis has never been measured in ME/CFS (Elevated Lactate in ME/CFS May Signal Through GPR81/HCAR1, Monocarboxylate Transporter Capacity as a Candidate Rate-Limiting Node). Lactate elevation is documented but compartment-specific rather than uniform — brain (anterior-cingulate) lactate is elevated on MRS while resting calf-muscle metabolites do not differ ((Godlewska et al. 2025)) — and whether it actively contributes to symptoms, as opposed to marking upstream energy failure, is unresolved (Does Dysregulated Lactate Signaling Contribute to ME/CFS Symptoms?). The candidate intervention levers are mechanistically distinct: supporting the PDH gate (thiamine) or fatty-acid oxidation (carnitine), or shifting substrate to ketones (MCT/ketogenic) are plausible routes to lower glycolytic lactate (Cofactor and Substrate Strategies May Lower Lactate in ME/CFS), whereas buffering lactate itself with bicarbonate is unsupported and potentially harmful (Buffering Lactate with Bicarbonate Is Not Supported). The binding constraint is measurement, not mechanism: no ME/CFS study has used lactate as an intervention endpoint, and the receptor/transporter axis and post-exertional clearance kinetics are unmeasured (Measure the GPR81/HCAR1 and MCT Axis in a Severity-Stratified ME/CFS Cohort, Post-Exertional Lactate Kinetics as a Monitoring Biomarker). The open question is therefore not whether lactate can be lowered, but whether lowering it changes anything for patients.
Consequence: It sets a clear research priority — measure the receptor axis and the clearance kinetics before treating lactate as a target — and warns patients that the intuitive fix (buffering the acid) is not supported.
4 Insulin Sensitivity
Insulin resistance features in some ME/CFS patients:
- Hyperinsulinemia: Compensatory insulin excess
- Impaired glucose tolerance: Abnormal oral glucose tolerance tests
- Metabolic syndrome overlap: Shared features in some patients
- Inflammation link: Cytokines promote insulin resistance